FierceBiotech

Pharmalucence Announces FDA Approval and Orphan Drug Designation for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Malignant Melanoma Patients

<0> Pharmalucence Announces FDA Approval and Orphan Drug Designation for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Malignant Melanoma Patients </0> Pharmalucence, Inc. () has received ...
FierceBiotech

Pharmalucence Announces FDA Approval for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Breast Cancer Patients

BEDFORD, Mass.--(BUSINESS WIRE)-- Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include ...
The Free Press Journal

Jubilant’s Radiopharma Business Receives ANDA Approval For Technetium Sulfur Colloid Injection

Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Draximage Inc (‘Company’) today announced that it has received approval from the US FDA with regards to the Company’s abbreviated new drug ...
EurekAlert!

Molecular breast imaging protocol unmasks more cancer

St. Louis, Mo. (June 9, 2014) – Patients with advanced breast cancer that may have spread to their lymph nodes could benefit from a more robust dose of a molecular imaging agent called Tc-99m filtered ...
Business Wire

Pharmalucence Announces FDA Approval and Orphan Drug Designation for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Malignant Melanoma Patients

BILLERICA, Mass.--(BUSINESS WIRE)--Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the indication for use of its Sulfur Colloid Injection (SCI) to include localization ...